MXPA06010805A - Formulacion de claritromicina de libracion prolongada. - Google Patents

Formulacion de claritromicina de libracion prolongada.

Info

Publication number
MXPA06010805A
MXPA06010805A MXPA06010805A MXPA06010805A MXPA06010805A MX PA06010805 A MXPA06010805 A MX PA06010805A MX PA06010805 A MXPA06010805 A MX PA06010805A MX PA06010805 A MXPA06010805 A MX PA06010805A MX PA06010805 A MXPA06010805 A MX PA06010805A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
polymers
erythromycin
Prior art date
Application number
MXPA06010805A
Other languages
English (en)
Spanish (es)
Inventor
Himadrisen
Suryakumar Jayanthi
Vineeth Raghavan
Nilesh Bhandari
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MXPA06010805A publication Critical patent/MXPA06010805A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
MXPA06010805A 2004-03-24 2005-03-17 Formulacion de claritromicina de libracion prolongada. MXPA06010805A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN356MU2004 2004-03-24
PCT/IN2005/000085 WO2005102289A1 (fr) 2004-03-24 2005-03-17 Formulation a liberation prolongee de clarithromycine

Publications (1)

Publication Number Publication Date
MXPA06010805A true MXPA06010805A (es) 2006-12-19

Family

ID=34979410

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06010805A MXPA06010805A (es) 2004-03-24 2005-03-17 Formulacion de claritromicina de libracion prolongada.

Country Status (5)

Country Link
EP (1) EP1732518A1 (fr)
AU (1) AU2005235237A1 (fr)
BR (1) BRPI0508743A (fr)
MX (1) MXPA06010805A (fr)
WO (1) WO2005102289A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2675724C (fr) * 2003-06-16 2012-12-04 Andrx Pharmaceuticals, Llc Composition orale a liberation prolongee
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
US8617596B2 (en) 2006-04-12 2013-12-31 Nippon Soda Co., Ltd. Sustained-release tablet production process
WO2008114143A1 (fr) * 2007-03-22 2008-09-25 Aurobindo Pharma Limited Formulations à libération prolongée d'un antibiotique macrolide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
CA2675724C (fr) * 2003-06-16 2012-12-04 Andrx Pharmaceuticals, Llc Composition orale a liberation prolongee
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition

Also Published As

Publication number Publication date
WO2005102289A1 (fr) 2005-11-03
AU2005235237A1 (en) 2005-11-03
BRPI0508743A (pt) 2008-01-22
EP1732518A1 (fr) 2006-12-20

Similar Documents

Publication Publication Date Title
US6515010B1 (en) Carvedilol methanesulfonate
AU731276B2 (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
ZA200309724B (en) Oral controlled release pharmaceutical composition for one a day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
AU2002314515A1 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
NZ555901A (en) Matrix type sustained-release preparation containing donepezil hydrochloride and / or memantine hydrochloride
HU204192B (en) Process for producing desintegrable gemfibrosil compositions of instant and prolonged delivery of the active component
KR20130091319A (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
WO2004019901A2 (fr) Composition pharmaceutique a liberation prolongee
HU204194B (en) Process for producing instant and retard gemfibrosil compositions
CZ20024216A3 (cs) Přípravky s chinolonovými antibiotiky s prodlouženým účinkem a způsob jejich výroby
WO2007086079B1 (fr) Forme de dose a liberation soutenue de derives de phenothiazine contenant un canalisateur
US7943585B2 (en) Extended release antibiotic composition
CA2833115C (fr) Compositions pharmaceutiques de raltegravir, procedes de preparation et utilisation de celles-ci
MXPA06010805A (es) Formulacion de claritromicina de libracion prolongada.
WO2007049291A1 (fr) Nouvelles formes solides de dosage de valsartan et d'hydrochlorothiazide
EP1720524A2 (fr) Comprimes a liberation prolongee de clarithromycine
WO2005092293A1 (fr) Formulations de metformine
WO2003011256A1 (fr) Composition pharmaceutique d'agent procinetique a liberation orale controlee
WO2013147135A1 (fr) Composition pharmaceutique à libération contrôlée
US20080220064A1 (en) Extended release matrix formulations of morphine
WO2005067895A1 (fr) Compositions pharmaceutiques a liberation controlee
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤
WO2022153330A1 (fr) Compositions pharmaceutiques comprenant de l'acalabrutinib
WO2023044024A1 (fr) Nouveau système d'administration de médicament à revêtement dépendant du ph